Dianthus Therapeutics (DNTH) Operating Expenses (2017 - 2025)

Dianthus Therapeutics' Operating Expenses history runs 9 years deep, the most recent figure standing at $40.7 million for Q3 2025.

• In Q3 2025, Operating Expenses rose 26.85% year-over-year to $40.7 million; the TTM figure through Dec 2025 stood at $110.1 million (up 1.89% YoY), while the FY2024 annual figure was $108.1 million, up 111.96% from the prior year.
• Operating Expenses was $40.7 million for Q3 2025 at Dianthus Therapeutics, up from $35.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $40.7 million in Q3 2025 to a low of $8.2 million in Q1 2023.
• Historically, Operating Expenses has averaged $21.4 million across 5 years, with a median of $18.7 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses slumped 65.77% in 2023, then surged 147.83% in 2024.
• A 5-year view of Operating Expenses shows it stood at $20.1 million in 2021, then plunged by 41.07% to $11.9 million in 2022, then advanced by 13.02% to $13.4 million in 2023, then soared by 147.83% to $33.2 million in 2024, then climbed by 22.39% to $40.7 million in 2025.
• The last three Operating Expenses figures came in at $40.7 million (Q3 2025), $35.1 million (Q2 2025), and $34.3 million (Q1 2025), per Business Quant data.